Scott Osur, MD
Allergy · Albany, NYNPI 1831190636
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,800 of the $10,924 with a category attached, or 80.6%. GSK accounts for 84.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $5,869 and has fallen 96.7% since, to $195 in 2025.
Across 44 payments — averaging $248.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$9K
- AstraZeneca$562
- Genentech USA, Inc.$260
- Merck$152
- ARS Pharmaceuticals Operations, Inc.$125
- Shire North American Group Inc$124
- plus $507 from 8 others
What the payments were for
- Consulting fees$500%
- Speaking & faculty fees$8,80081%
- Travel & lodging$390%
- Food & beverage$2,01718%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 12 | $9,194 |
| AstraZeneca | 12 | $562 |
| Genentech USA, Inc. | 2 | $260 |
| Merck | 3 | $152 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $125 |
| Shire North American Group Inc | 1 | $124 |
| Incyte Corporation | 1 | $123 |
| Optinose US, Inc. | 1 | $104 |
| Blueprint Medicines Corporation | 1 | $68 |
| Amgen | 3 | $60 |
| CSL Behring | 2 | $57 |
| Novartis | 2 | $52 |
| Kaleo, Inc. | 2 | $30 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,924 in reported general payments places this provider in the 75th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 16 | $54,943 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $46,623 |
| Arnuity ElliptaFluticasone Furoate | 48 | $23,358 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $17,268 |
| Fluticasone Propionate HfaFluticasone Propionate | 43 | $11,214 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $10,795 |
| DuleraMometasone/Formoterol | 12 | $7,967 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $7,707 |
| Epinephrine | 33 | $7,528 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $4,844 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $3,336 |
| Mometasone Furoate | 20 | $3,309 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $3,186 |
| Fluticasone Propionate | 102 | $2,736 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 24 | $1,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $9,194 | $87,248122 claims |
| MerckDulera | $152 | $7,96712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 92 allergy providers in New York.
Other allergy in Albany
- Michael KatlanAlbany$91K
- Janet ClaassenAlbany$1K
- Thomas FlaimAlbany$1K
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Yudhistira PersaudBronx$127K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.